Jackie Syrop

September 29, 2017

The standard way to conduct mobilization in hematopoietic stem cell donors relies on using 2 original granulocyte-colony stimulating factors (G-CSFs), filgrastim (Neupogen) and lenograstim (Granocyte).

September 28, 2017

A study by Cristina Scavone, MS, and colleagues, published in Frontiers in Pharmacology, concludes that most biologic drugs used to treat cancer, rheumatoid arthritis, and psoriatic arthritis in real-world clinical settings demonstrate overall good tolerability

September 27, 2017

A study of Japanese patients with ulcerative colitis who were naïve to anti–tumor necrosis factor treatment found that patients preferred adalimumab to infliximab, but the researchers also reported no differences in the efficacy of the 2 treatments.

September 26, 2017

A large Canadian study of patients with inflammatory diseases, including rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis, reports that a high overall rate of adherence to subcutaneous anti-TNFs.

September 25, 2017

The rituximab biosimilar CT-P10 (Celltrion and Teva’s Truxima), which is approved in the European Union and under review by the FDA in the United States, showed comparable effectiveness to reference rituximab (Genentech and Biogen’s innovator product, sold as Mabthera and Rituxan) in a network meta-analysis.

September 22, 2017

In real-world community oncology settings, bevacizumab-containing regimens were associated with longer progression-free survival and overall survival compared with non-bevacizumab regimens.

September 22, 2017

Trends in data concerning publicly and privately insured patients with rheumatoid arthritis show that the use of bioloigic disease-modifying antirheumatic drugs (DMARDs) is on the rise.

September 20, 2017

When a patient fails to respond or no longer responds to one biologic disease-modifying antirheumatic drug due to a lack of efficacy or poor tolerability, switching to another bDMARD can be a safe and effective treatment strategy.

September 19, 2017

A retrospective case series suggests that low-level anti-tumor necrosis factor anti-drug antibodies in patients with inflammatory bowel disease may be overcome by dose escalation and/or addition of an immunomodulator, which can allow for clinical improvement in disease status.

September 15, 2017

Social media posts by patients with Crohn’s disease are a useful data set to understand patient perspectives on treatment with infliximab (Remicade), according to a new study.